Pronostics in Austria and Germany agreement with Medipan
This article was originally published in Clinica
Executive Summary
Multiplexed diagnostics manufacturer Pronostics has signed up German medical device distributor Medipan, as the exclusive marketer of its UltraPlex assays in Germany and Austria. The deal will see Berlin-based Medipan distribute Pronostics' UltraPlex ANA, Coeliac and Thyroid autoimmune disease biomarker assays to hospitals and private laboratories throughout the two countries. According to Cambridge, UK-based Pronostics, the deal could initially generate around E2m ($3.2m) in revenue annually, however, no other financial details were disclosed. Pronostics claims that in 2005, the worldwide market for autoimmune tests was in the region of $250m and is expected to grow to around $410m by 2010. The UltraPlex ANA, the firm's lead technology, enables 11 tests to be carried out at once using a microscopic bar-coding system. This helps reduce time and costs, when compared to existing serial testing methods, such as Hep-2 screens and ELISA tests.
You may also be interested in...
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.